2025-01-31T12:03:21-06:00 2024-06-30 930900579 MCDONALD JACOBS PC 121 SW SALMON ST STE 1100 PORTLAND OR 97204 990 2023-07-01 930571472 NATIONAL PSORIASIS FOUNDATION NATI 5032447404 1800 DIAGONAL ROAD 360 ALEXANDRIA VA 22314 RONALD GOLDSMAN CHIEF FINANCIAL OFFICER 5032447404 2025-01-30 1 0 SANG AHN P00540880 5032270581 2023 2025-03-06 01:10:19Z LEAH MCCORMICK HOWARD 1800 DIAGONAL ROAD 360 ALEXANDRIA VA 22314 12755987 0 X WWW.PSORIASIS.ORG X 1968 VA TO DRIVE EFFORTS TO CURE PSORIATIC DISEASE AND IMPROVE THE LIVES OF THOSE AFFECTED. 21 18 68 640 1016015 357238 9711727 10084711 2024319 1933982 169130 207360 -313737 -630285 11591439 11595768 3419296 2930843 0 0 6451132 6312918 65763 233613 1455236 3827201 3109478 13763392 12586852 -2171953 -991084 13817026 14679906 4798376 5940214 9018650 8739692 X THE NATIONAL PSORIASIS FOUNDATION PROVIDES PEOPLE WITH PSORIASIS AND PSORIATIC ARTHRITIS THE SERVICES THEY NEED TO BEST MANAGE THEIR CONDITION, WHILE PROMOTING RESEARCH TO FIND A CURE. 0 0 3846872 2930843 RESEARCHNPF CONTINUED TO LEAD COLLABORATIVE, TRANSFORMATIONAL RESEARCH BY ENSURING THAT FUNDING EXTRAMURAL RESEARCH REMAINED A PRIORITY. IN FY 2024, NPF INVESTED OVER $2.9M IN RESEARCH GRANTS AND FELLOWSHIP AWARDS. INTRODUCED IN 2020, THE NPF HAS INVESTED OVER $4M TOWARDS THE PSORIASIS PREVENTION INITIATIVE GRANT, A STUDY AIMED AT PREVENTING THE ONSET ON CARDIOVASCULAR DISEASE IN PEOPLE WITH PSORIATIC DISEASE, AND TO PROVIDE, TIMELY, ADEQUATE TREATMENT FOR THOSE DEEMED TO BE AT HIGH RISK OF DEVELOPING CARDIOVASCULAR DISEASE. IN FY 2023, THE PILOT PHASE OF THE UNIVERSITY OF PENNSYLVANIA-LED STUDY ON CVD CONCLUDED AND PLANNING BEGAN FOR THE LAUNCH OF THE FULL STUDY. THIS UNIQUE, SCALABLE MODEL THAT TESTS CARE COORDINATION ACROSS DERMATOLOGISTS AND PRIMARY CARE PROVIDERS SAW PROMISING EARLY RESULTS IN THE PILOT STUDY. OF THE 25% OF PEOPLE IN PHASE ONE WHO WERE IDENTIFIED AS HAVING AS HIGH RISK FOR CARDIOVASCULAR DISEASE, 85% FOLLOWED THROUGH WITH AN APPOINTMENT WITH THEIR HEALTH CARE PROVIDER TO ADDRESS CARDIOVASCULAR DISEASE. THE PSA DIAGNOSTIC TEST GRANT WAS LAUNCHED IN 2020 WITH THE GOAL OF ADVANCING THE DEVELOPMENT OF THE FIRST DIAGNOSTIC TEST FOR PSA, REDUCING GUESSWORK AND LONG DELAYS IN DIAGNOSIS AND TREATMENT. AT THE CONCLUSION OF THE STUDY THIS FISCAL YEAR, KEY FINDINGS OF THE RESEARCH EVIDENCING THE CRITICAL ADVANCEMENTS IN UNDERSTANDING THE DISEASE TO HELP INFORM THE WORK OF OTHER RESEARCHERS AND CLINICIANS WERE PUBLISHED IN SCIENCE IMMUNOLOGY. THE NPF CONTINUED TO COLLABORATE WITH PUBLIC-PRIVATE PARTNERS IN THE ACCELERATED MEDICINES PARTNERSHIP FOR AUTOIMMUNE AND IMMUNE-MEDIATED DISEASES INITIATIVE, PUBLISHED SEVERAL ABSTRACTS AND PAPERS, AND BROUGHT THE INTERNALLY GENERATED DATA TO THE COMMUNITY. 1321080 12000 PROFESSIONAL EDUCATIONNPF CONTINUED TO EXPAND AND STRENGTHEN MEDICAL EDUCATION PROGRAMMING TARGETING HEALTH CARE PROVIDERS AT ALL LEVELS AND STAGES OF CAREER. THE 25TH ANNUAL NPF RESIDENTS' MEETING OFFERED DERMATOLOGY RESIDENTS THE LATEST IN PSORIATIC DISEASE TREATMENT PRESENTED BY EXPERTS IN THE FIELD. NPF ALSO LAUNCHED A COMPLIMENTARY RHEUMATOLOGY FELLOWS MEETING TO OFFER EDUCATION TO NEXT GENERATION RHEUMATOLOGISTS AND DEVELOP THE RELATIONSHIPS BETWEEN THESE FUTURE CARE COLLABORATORS. THE NPF HOSTED ITS BI-ANNUAL NPF RESEARCH SYMPOSIUM: A CURE FOR ALL, THE NATION'S PREMIER PSORIATIC DISEASE RESEARCH EVENT WHICH FEATURED SPEAKERS ON A WIDE ARRAY OF CURRENT TOPICS FROM THE PSORIASIS TO PSA TRANSITION TO THE RESULTS OF A NOVEL KNOCKOUT STUDY AIMING TO CLEAR PSORIASIS SYMPTOMS WITH EARLY AGGRESSIVE BIOLOGIC TREATMENT.THROUGH ITS DEDICATION TO EDUCATING HEALTH CARE PROVIDERS ON PSORIATIC DISEASE AND ITS RELATED DISEASES, NPF HAS EARNED ACCREDITATION AS A PROVIDER OF CONTINUING MEDICAL EDUCATION. IT'S PART OF OUR EFFORTS TO ENSURE ALL DIFFERENT TYPES OF HEALTH CARE PROVIDERS UNDERSTAND THIS COMPLICATED DISEASE. NPF OFFERS THE PSOUND BYTES CONTINUING MEDICAL EDUCATION PODCASTS, WEBINARS, AND IN-PERSON CLASSES AND SEMINARS FOR A WIDE RANGE OF AUDIENCES AND PUBLISHES THE JOURNAL OF PSORIASIS AND PSORIATIC ARTHRITIS, A PEER REVIEWED OUTLET FEATURING CME ARTICLES. 1063418 ADVOCACYNPF CONTINUED TO ADVOCATE ON BOTH STEP THERAPY AND COPAY ACCUMULATOR ADJUSTMENT PROGRAMS TO ENSURE PATIENTS HAVE AFFORDABLE ACCESS TO THERAPIES. NPF ALSO LEVERAGED THOUSANDS OF ADVOCATES TO WORK FOR HEALTH INSURANCE COVERAGE IMPROVEMENTS FOR THE MILLIONS OF PEOPLE LIVING WITH PSORIATIC DISEASE, WHILE ALSO WORKING TO IMPROVE THE SAFETY AND AFFORDABILITY OF PSORIASIS AND PSA TREATMENTS AND INCREASING FEDERAL SUPPORT FOR PSORIATIC DISEASE RESEARCH. 3460775 906229 EDUCATION, OUTREACH, AND PATIENT SERVICESTHE NPF IS PROUD TO HAVE PUBLISHED THE FIRST EVER PSORIASIS HEALTH INDICATOR REPORT. THIS SET OF DATA ABOUT PSORIATIC DISEASE AND ITS IMPACTS WAS MADE POSSIBLE BY A PARTNERSHIP WITH THE CENTERS FOR DISEASE CONTROL AND THROUGH THE CONTRIBUTIONS OF TODAY'S LEADERS IN DERMATOLOGY AND RHEUMATOLOGY RESEARCH AND CLINICAL CARE. THE PSORIASIS HEALTH INDICATOR REPORT PROVIDES INFORMATION NEEDED TO EDUCATE THE GENERAL PUBLIC, HEALTH OFFICIALS, AND HEALTH CARE PROVIDERS ABOUT KEY ISSUES AND CHALLENGES AFFECTING THE MORE THAN 8 MILLION PEOPLE IN THE U.S. WHO LIVE WITH THIS DISEASE. SINCE 2016, NPF'S PATIENT NAVIGATION CENTER HAS SUPPORTED OVER 90,000 PATIENTS AND THEIR CAREGIVERS WITH FREE, PERSONALIZED SUPPORT DESIGNED TO HELP THEM UNDERSTAND PSORIATIC DISEASE AND TREATMENT OPTIONS, NAVIGATE INSURANCE CHALLENGES, AND FIND THE APPROPRIATE HEALTH CARE PROVIDER. NPF ADVANCE MAGAZINE CONTINUED TO PROVIDE THE LATEST INFORMATION, STORIES, AND RESOURCES FIVE TIMES ANNUALLY FOR OVER 25,000 PRINT SUBSCRIBERS AND HUNDREDS OF THOUSANDS OF ONLINE READERS. EACH WEEK, MORE THAN 283,000 PEOPLE RECEIVED ADVANCE WEEKLY, THE OFFICIAL PATIENT-FOCUSED E-NEWSLETTER OF NPF. 3460775 906229 9692145 1 1 0 1 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 1 1 0 1 1 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 68 1 1 1 0 0 0 0 1 1 0 0 0 0 0 0 X 21 18 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 AL AK AZ AR CA CO CT DE DC FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN TX UT VT VA WA WV WI WY X X RONALD GOLDSMAN 5032447404 1800 DIAGONAL ROAD 360 ALEXANDRIA VA 22314 LEAH MCCORMICK HOWARD PRESIDENT/CEO 40.00 X 304524 0 35435 RANDY BERANEK THRU DEC 2021 FORMER PRESIDENT/CEO 40.00 X 53802 0 0 RONALD GOLDSMAN CHIEF FINANCIAL OFFICER 40.00 X 214283 0 18621 JENNIFER FAGERSTROM CHIEF REVENUE OFFICER 40.00 X 227737 0 39539 GUY EAKIN CHIEF SCIENTIFIC & MEDICAL OFFICER 40.00 X 153257 0 12559 RENE ISLAS CHIEF OF STAFF 40.00 X 140595 0 26666 JASON HARRIS VICE PRESIDENT OF GOVERNMENT RELATIONS & ADVOCACY 40.00 X 153312 0 18346 KATHERINE SOUTHWICK VICE PRESIDENT OF MARKETING & COMMUNICATIONS 40.00 X 136394 0 16100 BREANNA BAER VICE PRESIDENT, FIELD DEVELOPMENT & OPERATIONS 40.00 X 141302 0 22187 ROBERT FRIESEL DIRECTOR OF RESEARCH & MEDICAL AFFAIRS 40.00 X 125719 0 20882 CAROL OSTROW CHAIR-ELECT 1.00 X X 0 0 0 EYAL OFIR VICE CHAIR 1.00 X X 0 0 0 MIKE REFERMAT TREASURER 1.00 X X 0 0 0 RICHARD SEIDEN SECRETARY 1.00 X X 0 0 0 RON GRAU PAST CHAIR 1.00 X X 0 0 0 JONATHAN SCOTT DIRECTOR 1.00 X 0 0 0 LARRY GREEN MD DIRECTOR 1.00 X 0 0 0 MARY CARROLL DIRECTOR 1.00 X 0 0 0 MICHAEL GRAFF DIRECTOR 1.00 X 0 0 0 MARK OBERMAN DIRECTOR 1.00 X 0 0 0 JASON LICHTEN MD DIRECTOR 1.00 X 0 0 0 PETE MILLER THRU MARCH 2023 DIRECTOR 1.00 X 0 0 0 MATTHEW T KISELICA DIRECTOR 1.00 X 0 0 0 APRIL ARMSTRONG MD THRU JUNE 2023 DIRECTOR 1.00 X 0 0 0 ELAINE HUSNI MD DIRECTOR 1.00 X 0 0 0 VALERIE HARRISON FROM JUNE 2023 DIRECTOR 1.00 X 0 0 0 DIANA SANDLER FROM JUNE 2023 DIRECTOR 1.00 X 0 0 0 BRIAN JANSSEN FROM JUNE 2023 DIRECTOR 1.00 X 0 0 0 1650925 0 210335 17 1 1 0 NEXUS DIRECT LLC 780 LYNNHAVEN PARKWAY SUITE 400 VIRGINIA BEACH VA 23452 DIRECT MARKETING AGENCY 440323 CONVERO 201 N UNION STREET SUITE 110 ALEXANDRIA VA 22314 PUBLIC RELATIONS 117400 MILLER NASH LLP 1140 SW WASHINGTON ST SUITE 700 PORTLAND OR 97205 LEGAL 109612 3 174 30933 2702831 395842 6954931 25559 10084711 ADVERTISING INCOME 541800 1016015 1016015 PRODUCT CERTIFICATION 541900 484392 484392 PATIENT RECRUITMENT 541900 369983 369983 ROYALTIES 541900 38299 38299 SCIENTIFIC ADVISORY 541900 12000 12000 13293 13293 1933982 318103 318103 418929 529672 -110743 -110743 -110743 0 2702831 630547 -630547 -630547 262 0 262 262 11595768 918229 1016015 -423187 2293189 2293189 637654 637654 1143882 814346 209199 120337 4250383 3025907 777332 447144 191293 136184 34985 20124 333980 237765 61080 35135 393380 280053 71943 41384 48101 32709 9620 5772 18605 12651 3721 2233 245323 245323 233613 233613 31857 31857 407613 373998 20422 13193 278941 267836 11105 67711 34320 6921 26470 155087 110409 28363 16315 918956 691360 11519 216077 50214 35748 9183 5283 57871 41199 10584 6088 DUES AND SUBSCRIPTIONS 363879 271326 25987 66566 PRINTING AND POSTAGE 205310 93176 2181 109953 TAXES 92486 92486 BANK FEES 76714 20293 56421 90810 56992 11795 22023 12586852 9692145 1439471 1455236 X 2155746 1023562 1788781 2461795 703034 443481 4370 2630 152539 226382 474439 250562 385368 223877 8511304 9620108 115884 678071 13817026 14679906 617899 952666 3845657 4024290 168500 121375 166320 841883 4798376 5940214 X 5506333 5271417 3512317 3468275 9018650 8739692 13817026 14679906 X -991084 798596 -86470 X X 0 1 X 1 0 X 12708368 11146561 11642853 9711727 10084711 55294220 12708368 11146561 11642853 9711727 10084711 55294220 18249687 37044533 216849 164668 214822 284300 318102 1198741 1291031 1065032 185995 311307 397931 3251296 59744257 4178892 0.62010 0.61160 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 49093 196230 245323 10854436 11099759 704988 176247 0 0 616452 711018 763609 704988 2796067 4194101 199263 153665 229678 245323 827929 154113 177755 190902 176247 699017 1048526 25348 69888 79586 49093 223915 SCHEDULE C, PART II-A, LINE 1 OUR ADVOCACY TEAM IS LED BY GOVERNMENT RELATIONS EXPERTS THAT TRACK AND IDENTIFY STATE AND FEDERAL OPPORTUNITIES TO SPEAK UP ON BEHALF OF THE OVER 8 MILLION AMERICANS LIVING WITH PSORIATIC DISEASE. WE DEVELOP POSITION STATEMENTS THAT OUR STAFF AND VOLUNTEERS CAN TAKE INTO MEETINGS WITH POLICYMAKERS. WE WORK WITH VARIOUS STAKEHOLDERS, INCLUDING GOVERNMENT OFFICIALS, INSURERS, PHARMACY BENEFIT MANAGERS, PHARMACEUTICAL MANUFACTURERS, AND EMPLOYERS, TO SPREAD AWARENESS ABOUT THE DAY-TO-DAY CHALLENGES OF LIVING WITH PSORIATIC DISEASE AND ADVOCATE ON BEHALF OF POLICY CHANGES THAT ELIMINATE ACCESS TO CARE BARRIERS. EACH YEAR, THE FOUNDATION HOLDS A CAPITOL HILL DAY TO ADVOCATE FOR POLICIES THAT IMPROVE ACCESS TO CARE. 100000 100000 179272 118696 60576 195167 131866 63301 223877 DEFERRED COMPENSATION PLAN 88781 OPERATING LEASE 753102 841883 X 12365507 798596 3000 801596 11563911 31857 31857 11595768 12644465 3000 102000 105000 12539465 31857 15530 47387 12586852 PART X, LINE 2: THE ORGANIZATION FOLLOWS THE PROVISION OF FASB ASC TOPIC 740 OF ACCOUNTING FOR UNCERTAINTY IN INCOME TAXES. MANAGEMENT HAS EVALUATED THE ORGANIZATION'S TAX POSITIONS AND CONCLUDED THAT THERE ARE NO UNCERTAIN TAX POSITIONS THAT REQUIRE ADJUSTMENT TO THE FINANCIAL STATEMENTS TO COMPLY WITH PROVISIONS OF THIS TOPIC. PART XII, LINE 2D - OTHER ADJUSTMENTS: LOSS FROM UNCOLLECTIBLES INCLUDED AS A CHANGE IN NET ASSETS ON FORM 990 102,000. PART XII, LINE 4B - OTHER ADJUSTMENTS: GRANT TURNBACKS NETTED WITH EXPENSES ON FINANCIAL STATEMENTS 15,530. 0 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM 0 0 GRANT EXPENSES DISCOVERY AND EARLY CAREER RESEARCH GRANT 89000 NORTH AMERICA - CANADA AND MEXICO, BUT NOT THE UNITED STATES 0 0 GRANT EXPENSES PSA DIAGNOSTIC AWARD 423654 EAST ASIA AND THE PACIFIC 0 0 GRANT EXPENSE EARLY CAREER RESEARCH GRANT 50000 MIDDLE EAST AND NORTH AFRICA 0 0 DISCOVERY GRANT DISCOVERY GRANT 75000 0 0 0 0 0 0 637654 0 637654 MIDDLE EAST AND NORTH AFRICA DISCOVERY GRANT 75000 BANK DRAFT 0 EUROPE (INCLUDING ICELAND & GREENLAND) DISCOVERY GRANT 72000 BANK DRAFT 0 EUROPE (INCLUDING ICELAND & GREENLAND) EARLY CAREER RESEARCH GRANT 17000 BANK DRAFT 0 NORTH AMERICA (CANADA AND MEXICO, BUT NOT U.S.) TRANSLATIONAL RESEARCH GRANT 199510 BANK DRAFT 0 NORTH AMERICA (CANADA AND MEXICO, BUT NOT U.S.) PSORIATIC DISEASE RESEARCH FELLOWSHIP GRANT 50000 BANK DRAFT 0 NORTH AMERICA (CANADA AND MEXICO, BUT NOT U.S.) EARLY CAREER RESEARCH GRANT 50000 BANK DRAFT 0 NORTH AMERICA (CANADA AND MEXICO, BUT NOT U.S.) PSORIATIC DISEASE RESEARCH FELLOWSHIP GRANT 49710 BANK DRAFT 0 NORTH AMERICA (CANADA AND MEXICO, BUT NOT U.S.) DISCOVERY GRANT 74434 BANK DRAFT 0 EAST ASIA AND THE PACIFIC EARLY CAREER RESEARCH GRANT 50000 BANK DRAFT 0 0 9 0 0 0 0 0 0 PART I, LINE 2: GRANT RECIPIENTS WITH MULTI-YEAR AWARDS PROVIDE INTERIM SCIENTIFIC AND PROGRESS REPORTS. ALL GRANT RECIPIENTS PROVIDE A FINAL SCIENTIFIC REPORT AND ACCOUNTING AT THE CONCLUSION OF THE RESEARCH TERM. THE INTERIM AND FINAL REPORTS ARE REVIEWED BY THE RESEARCH DEPARTMENT. X X X X X X 1 NEXUS DIRECT LLC 780 LYNNHAVEN PARKWAY SUITE 400 VIRGINIA BEACH VA 23452 DIRECT MAIL 0 403454 233613 169841 403454 233613 169841 AL AK AZ AR CA CO CT DE FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN TX UT VT VA WA WV WI WY PEER TO PEER (TAKE ACTION/TEAM NPF) 905365 905365 11505 14926 7773 13209 56584 COMMIT TO CURE GALA 777887 777887 5837 28577 14883 16551 72110 1 1019579 1019579 6634 155038 80742 41586 104592 2702831 2702831 23976 198541 103398 71346 233286 630547 -630547 SCHEDULE G, PART II, COLUMN A, EVENT #1 NAME OF EVENT: PEER TO PEER (TAKE ACTION & TEAM NPF) SCHEDULE G, PART II, COLUMN B, EVENT #2 NAME OF EVENT: COMMIT TO CURE GALA SCHEDULE G, PART II, COLUMN C, OTHER EVENTS NAME OF EVENT: OTHER COMMUNITY BUILDING SPECIAL EVENTS 1 BRIGHAM AND WOMEN'S HOSPTAL INC 75 FRANCIS STREET BOSTON MA 02115 900656139 501 (C)(3) 50000 0 BRIDGE GRANT FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH 11400 ROCKVILLE PIKE SUITE 600 NORTH BETHESDA MD 20852 521986675 501 (C)(3) 100000 0 AMP AIM GRANT ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI ONE GUSTAVE L LEVY PLACE NEW YORK NY 10029 136171197 501 (C)(3) 200000 0 TRANSLATIONAL RESEARCH AWARD BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 485 BROADWAY MAIL CODE 8838 REDWOOD CITY CA 94063 941156365 501 (C)(3) 75000 0 DISCOVERY GRANT AWARD REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO 1855 FOLSOM STREET STE 425 SAN FRANCISCO CA 941034249 946036493 501 (C)(3) 49999 0 PSORIATIC DISEASE RESEARCH FELLOWSHIP GRANT REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO 1855 FOLSOM STREET STE 425 SAN FRANCISCO CA 941034249 946036493 501 (C)(3) 75000 0 DISCOVERY GRANT AWARD REGENTS OF THE UNIVERSITY OF CALIFORNIA LOS ANGELES 595 CHARLES E YOUNG DR E LOS ANGELES CA 90095 956006143 501 (C)(3) 32000 0 PSORIATIC DISEASE RESEARCH FELLOWSHIP GRANT REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DRIVE LA JOLLA CA 92093 946036493 501 (C)(3) 50000 0 EARLY CAREER RESEARCH GRANT TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA PO BOX 785541 PHILADELPHIA PA 19178 231352685 501 (C)(3) 1111190 0 PPI AWARD UNIVERSITY OF PITTSBURGH 4200 FIFTH AVENUE PITTSBURGH PA 15260 250965591 501 (C)(3) 100000 0 BRIDGE GRANT UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER 5323 HARRY HINES BLVS DALLAS TX 75390 752556007 501 (C)(3) 75000 0 DISCOVERY GRANT AWARD UNIVERSITY OF UTAH 201 PRESIDENTS CIRCLE SALT LAKE CITY UT 84112 876000525 501 (C)(3) 200000 0 TRANSLATIONAL RESEARCH AWARD VANDERBILT UNIVERSITY MEDICAL CENTER 1211 MEDICAL CENTER DR NASHVILLE TN 37232 352528741 501 (C)(3) 100000 0 BRIDGE GRANT WASHINGTON UNIVERSITY IN ST LOUIS 700 ROSEDALE AVENUE SAINT LOUIS MO 63130 430653611 501 (C)(3) 75000 0 DISCOVERY GRANT AWARD 14 0 PART I, LINE 2: GRANT RECIPIENTS WITH MULTI-YEAR AWARDS PROVIDE INTERIM SCIENTIFIC AND FISCAL PROGRESS REPORTS. ALL GRANT RECIPIENTS PROVIDE A FINAL SCIENTIFIC REPORT AND ACCOUNTING AT THE CONCLUSION OF THE RESEARCH TERM. THE INTERIM AND FINAL REPORTS ARE REVIEWED BY THE RESEARCH DEPARTMENT. X X X X 1 1 0 0 0 0 0 0 0 LEAH MCCORMICK HOWARD PRESIDENT/CEO 304524 0 0 0 0 0 32715 0 2720 0 339959 0 0 0 RANDY BERANEK THRU DEC 2021 FORMER PRESIDENT/CEO 0 0 0 0 53802 0 0 0 0 0 53802 0 0 0 RONALD GOLDSMAN CHIEF FINANCIAL OFFICER 214283 0 0 0 0 0 17024 0 1597 0 232904 0 0 0 JENNIFER FAGERSTROM CHIEF REVENUE OFFICER 227737 0 0 0 0 0 24254 0 15285 0 267276 0 0 0 GUY EAKIN CHIEF SCIENTIFIC & MEDICAL OFFICER 153257 0 0 0 0 0 6563 0 5996 0 165816 0 0 0 RENE ISLAS CHIEF OF STAFF 105042 0 0 0 35553 0 7552 0 19114 0 167261 0 0 0 JASON HARRIS VICE PRESIDENT OF GOVERNMENT RELATIO 153312 0 0 0 0 0 8882 0 9464 0 171658 0 0 0 KATHERINE SOUTHWICK VICE PRESIDENT OF MARKETING & COMMUN 136394 0 0 0 0 0 6789 0 9311 0 152494 0 0 0 BREANNA BAER VICE PRESIDENT, FIELD DEVELOPMENT & 141302 0 0 0 0 0 7450 0 14737 0 163489 0 0 0 PART I, LINES 4A-B RANDY BERANAK RECEIVED A FINAL COMPENSATION PAYMENT OF $53,802 THAT WAS PAID OUT OVER TIME. EMPLOYER CONTRIBUTIONS TO 457(F): LEAH MCCORMICK HOWARD - $17,500 JENNIFER FAGERSTROM - $12,500 RONALD GOLDSMAN - $10,000 X 4 25559 FMV ON DATE RECEIVED 1 0 1 1 PART I, LINE 32B: THE ORGANIZATION ENGAGES WITH OUTSIDE THIRD PARTIES WHEN ACCEPTING REAL ESTATE DONATIONS. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS REVIEWED BY THE GOVERNANCE & AUDIT COMMITTEE AND IS SHARED WITH ALL BOARD MEMBERS PRIOR TO ITS BEING FILED ELECTRONICALLY WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C WE HAVE A CONFLICT OF INTEREST POLICY THAT IS SIGNED BY ALL DIRECTORS ANNUALLY. ALL DIRECTORS AND KEY EMPLOYEES REFRAIN FROM VOTING OR COMMENTING ON ANYTHING WHERE THERE COULD BE A CONFLICT. FORM 990, PART VI, SECTION B, LINE 15 THE FOUNDATION SUBSCRIBES TO A SALARY SURVEY FOR COMPARABLE INFORMATION FOR SALARIES. FORM 990, PART VI, SECTION C, LINE 19 GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST. AUDITED FINANCIAL STATEMENTS ARE ALSO DISPLAYED ON THE WEBSITE. FORM 990, PART XI, LINE 9: GRANT TURNBACKS NETTED WITH EXPENSES 15,530. LOSS FROM UNCOLLECTIBLES -102,000. FORM 990, PART XII, LINE 2C THE PROCESS HAS NOT CHANGED FROM THE PRIOR YEAR.